Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $37.9286.

A number of equities research analysts recently commented on GMAB shares. The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Truist Financial started coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price for the company. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Wells Fargo & Company started coverage on shares of Genmab A/S in a research note on Monday, March 2nd. They set an “overweight” rating and a $40.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Genmab A/S in a research note on Tuesday, June 23rd.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Terra Nova Asset Management LLC acquired a new position in Genmab A/S during the 4th quarter valued at approximately $1,866,000. Perpetual Ltd acquired a new position in Genmab A/S during the 4th quarter valued at approximately $25,478,000. Assetmark Inc. increased its stake in Genmab A/S by 2,423.8% during the 4th quarter. Assetmark Inc. now owns 233,852 shares of the company’s stock valued at $7,203,000 after purchasing an additional 224,586 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Genmab A/S during the 4th quarter valued at approximately $1,331,000. Finally, Oppenheimer Asset Management Inc. increased its stake in Genmab A/S by 15.5% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 364,756 shares of the company’s stock valued at $11,234,000 after purchasing an additional 48,894 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Trading Down 0.4%

NASDAQ:GMAB opened at $26.02 on Tuesday. Genmab A/S has a 52 week low of $20.23 and a 52 week high of $35.43. The firm has a 50 day moving average of $26.18 and a 200 day moving average of $28.75. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $16.22 billion, a price-to-earnings ratio of 19.71, a PEG ratio of 1.66 and a beta of 0.85.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.